Pre-dosing with unlabelled antibody significantly increases the pharmacokinetic exposure but protects against myelosuppression of 177lu-lilotomab in non-hodgkin b-cell lymphoma patients. Kolstad, A, Madsbu, U, Stokke, C, Bach-Gansmo, T, Londalen, A M., Holtedahl, J., Revheim, M., Bruland, O, Dahle, J, Curtis, L B., & others In HAEMATOLOGICA, volume 101, pages 482–482, 2016. FERRATA STORTI FOUNDATION VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY.
bibtex   
@inproceedings{kolstad2016pre,
  title={Pre-dosing with unlabelled antibody significantly increases the pharmacokinetic exposure but protects against myelosuppression of 177lu-lilotomab in non-hodgkin b-cell lymphoma patients},
  author={Kolstad, A and Madsbu, U and Stokke, C and Bach-Gansmo, T and Londalen, A Muftuler and Holtedahl, JE and Revheim, ME and Bruland, O and Dahle, J and Curtis, L Baylor and others},
  booktitle={HAEMATOLOGICA},
  volume={101},
  pages={482--482},
  year={2016},
  organization={FERRATA STORTI FOUNDATION VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY}
}

Downloads: 0